LeMaitre Vascular Executive Sells Shares Amid Strong Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy LMAT?
Source: NASDAQ.COM
- Transaction Overview: On March 11, 2026, Trent G Kamke, Senior Vice President of Operations at LeMaitre Vascular, exercised and sold 2,625 shares of common stock for approximately $285,000, at a weighted average price of $108.50 per share, reflecting the company's strong stock performance.
- Ownership Change: This transaction reduced Kamke's direct holdings to 6,677 shares, representing 28.22% of his previous stake, indicating a significant shift in his equity position that could influence future decision-making and incentive structures.
- Financial Performance Highlights: LeMaitre reported a 16% year-over-year sales increase to $64.5 million in Q4 2025, with earnings rising 39% to $0.68 per share, supporting a 25% dividend increase, showcasing the company's robust growth potential in the medical device sector.
- Future Outlook: The company expects a 12% sales growth and a 22% increase in adjusted earnings for 2026, indicating LeMaitre Vascular's competitive strength and ongoing profitability, although analysts remain cautious about its future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LMAT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LMAT
Wall Street analysts forecast LMAT stock price to fall
7 Analyst Rating
4 Buy
3 Hold
0 Sell
Moderate Buy
Current: 108.750
Low
93.00
Averages
105.20
High
120.00
Current: 108.750
Low
93.00
Averages
105.20
High
120.00
About LMAT
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and other specialties, such as cardiac surgeons, general surgeons, and neurosurgeons. Its portfolio of product lines is used to treat vascular disease, which used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy and occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. Its principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. Its product offerings are sold primarily in the United States, Europe, Canada, and Asia Pacific.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
LeMaitre Vascular Executive Sells Shares Amid Strong Growth
- Transaction Overview: On March 11, 2026, Trent G Kamke, Senior Vice President of Operations at LeMaitre Vascular, exercised and sold 2,625 shares of common stock for approximately $285,000, at a weighted average price of $108.50 per share, reflecting the company's strong stock performance.
- Ownership Change: This transaction reduced Kamke's direct holdings to 6,677 shares, representing 28.22% of his previous stake, indicating a significant shift in his equity position that could influence future decision-making and incentive structures.
- Financial Performance Highlights: LeMaitre reported a 16% year-over-year sales increase to $64.5 million in Q4 2025, with earnings rising 39% to $0.68 per share, supporting a 25% dividend increase, showcasing the company's robust growth potential in the medical device sector.
- Future Outlook: The company expects a 12% sales growth and a 22% increase in adjusted earnings for 2026, indicating LeMaitre Vascular's competitive strength and ongoing profitability, although analysts remain cautious about its future performance.
See More
LeMaitre Vascular Executive Stock Transaction Analysis
- Executive Stock Transaction: On March 11, 2026, LeMaitre Vascular's Senior Vice President Trent G Kamke sold 2,625 shares of common stock for approximately $285,000, reflecting a common practice among executives to monetize equity awards while adhering to company trading policies.
- Ownership Changes: Kamke's direct holdings decreased from about 9,000 shares to 6,677 shares, marking a 28.22% reduction in direct equity exposure, yet he retains 1,353 stock options that can be exercised for additional shares, preserving potential upside alignment with company performance.
- Company Financial Performance: In Q4 2025, LeMaitre reported a 16% year-over-year sales increase to $64.5 million, with earnings rising 39% to $0.68 per share, supporting a 25% dividend increase, showcasing the company's strong growth in the medical device sector.
- Future Outlook: The company anticipates a 12% sales growth and a 22% increase in adjusted earnings for 2026, indicating LeMaitre Vascular's ongoing growth potential in the medical device market, which enhances investor confidence in its future performance.
See More
LeMaitre Vascular Executive Stock Transaction Overview
- Executive Stock Transaction: Trent G. Kamke, Senior VP of Operations at LeMaitre Vascular, exercised and immediately sold 2,625 shares of common stock on March 11, 2026, for approximately $285,000, indicating executive focus on liquidity.
- Ownership Change: Following the transaction, Kamke's direct holdings decreased to 6,677 shares, reflecting that this sale represented 28.22% of his pre-sale direct holdings, aligning with his recent trading patterns and demonstrating confidence in the market.
- Company Financial Performance: LeMaitre Vascular reported a 16% increase in fourth-quarter sales to $64.5 million and a 47% surge in operating income to $18.8 million, showcasing strong pricing power and manufacturing efficiencies that boosted overall performance.
- Future Outlook: The company projects approximately $280 million in full-year sales for 2026, raised its dividend by 25%, and initiated a $100 million buyback program, indicating strong confidence in future growth and commitment to shareholder returns.
See More
LeMaitre Vascular Executive Sells Shares
- Executive Share Sale: Trent G. Kamke, Senior VP of Operations at LeMaitre Vascular, sold 2,625 shares on March 11, 2026, for approximately $285,000, representing 28.22% of his direct holdings, reducing his position to 6,677 shares.
- Transaction Context: This sale involved only direct holdings and was executed through options conversion, indicating a typical liquidity event rather than a red flag for the company's fundamentals, especially given the stock's recent strong performance.
- Performance Drivers: LeMaitre Vascular reported a 16% increase in fourth-quarter sales to $64.5 million and a 47% surge in operating income to $18.8 million, driven by strong pricing and manufacturing efficiencies, highlighting its competitive edge in the global peripheral vascular market.
- Future Outlook and Risks: While the company projects approximately $280 million in full-year sales for 2026 and has raised its dividend by 25% alongside a $100 million buyback program, potential valuation creep remains a concern if growth slows, despite a strong operational outlook.
See More
LeMaitre Vascular to Participate in Five Investor Conferences
- Investor Conference Schedule: LeMaitre Vascular will participate in five investor conferences in March 2026, including the Leerink Partners Global Healthcare Conference on March 10, where management will present at 1:00 PM EDT to enhance the company's visibility among investors.
- Detailed Agenda: Following that, management will present at the Citizens Life Sciences Conference on March 11 at 1:40 PM, and will be available for one-on-one meetings at the Barclays Annual Global Healthcare Conference on March 12, further strengthening investor engagement.
- Virtual Forum Participation: At the KeyBanc Capital Markets Healthcare Forum on March 17, management will present virtually at 3:45 PM, showcasing the company's innovations and market potential in treating peripheral vascular disease.
- ROTH Conference Involvement: LeMaitre will also be available for one-on-one meetings and may participate in a presentation or fireside chat at the 38th Annual ROTH Conference from March 22-24, further expanding communication channels with investors.
See More
LeMaitre Vascular (LMAT.US) Officer Plans to Sell $10.35 Million in Common Stock via Form 144
- Stock Sale Announcement: Officer LeMaitre George intends to sell 100,000 shares of its common stock on February 26.
- Market Value: The total market value of the shares being sold is approximately $10.35 million.
See More
LeMaitre Vascular Executive Sells Shares Amid Strong Growth
- Transaction Overview: On March 11, 2026, Trent G Kamke, Senior Vice President of Operations at LeMaitre Vascular, exercised and sold 2,625 shares of common stock for approximately $285,000, at a weighted average price of $108.50 per share, reflecting the company's strong stock performance.
- Ownership Change: This transaction reduced Kamke's direct holdings to 6,677 shares, representing 28.22% of his previous stake, indicating a significant shift in his equity position that could influence future decision-making and incentive structures.
- Financial Performance Highlights: LeMaitre reported a 16% year-over-year sales increase to $64.5 million in Q4 2025, with earnings rising 39% to $0.68 per share, supporting a 25% dividend increase, showcasing the company's robust growth potential in the medical device sector.
- Future Outlook: The company expects a 12% sales growth and a 22% increase in adjusted earnings for 2026, indicating LeMaitre Vascular's competitive strength and ongoing profitability, although analysts remain cautious about its future performance.
See More
LeMaitre Vascular Executive Stock Transaction Analysis
- Executive Stock Transaction: On March 11, 2026, LeMaitre Vascular's Senior Vice President Trent G Kamke sold 2,625 shares of common stock for approximately $285,000, reflecting a common practice among executives to monetize equity awards while adhering to company trading policies.
- Ownership Changes: Kamke's direct holdings decreased from about 9,000 shares to 6,677 shares, marking a 28.22% reduction in direct equity exposure, yet he retains 1,353 stock options that can be exercised for additional shares, preserving potential upside alignment with company performance.
- Company Financial Performance: In Q4 2025, LeMaitre reported a 16% year-over-year sales increase to $64.5 million, with earnings rising 39% to $0.68 per share, supporting a 25% dividend increase, showcasing the company's strong growth in the medical device sector.
- Future Outlook: The company anticipates a 12% sales growth and a 22% increase in adjusted earnings for 2026, indicating LeMaitre Vascular's ongoing growth potential in the medical device market, which enhances investor confidence in its future performance.
See More
LeMaitre Vascular Executive Stock Transaction Overview
- Executive Stock Transaction: Trent G. Kamke, Senior VP of Operations at LeMaitre Vascular, exercised and immediately sold 2,625 shares of common stock on March 11, 2026, for approximately $285,000, indicating executive focus on liquidity.
- Ownership Change: Following the transaction, Kamke's direct holdings decreased to 6,677 shares, reflecting that this sale represented 28.22% of his pre-sale direct holdings, aligning with his recent trading patterns and demonstrating confidence in the market.
- Company Financial Performance: LeMaitre Vascular reported a 16% increase in fourth-quarter sales to $64.5 million and a 47% surge in operating income to $18.8 million, showcasing strong pricing power and manufacturing efficiencies that boosted overall performance.
- Future Outlook: The company projects approximately $280 million in full-year sales for 2026, raised its dividend by 25%, and initiated a $100 million buyback program, indicating strong confidence in future growth and commitment to shareholder returns.
See More
LeMaitre Vascular Executive Sells Shares
- Executive Share Sale: Trent G. Kamke, Senior VP of Operations at LeMaitre Vascular, sold 2,625 shares on March 11, 2026, for approximately $285,000, representing 28.22% of his direct holdings, reducing his position to 6,677 shares.
- Transaction Context: This sale involved only direct holdings and was executed through options conversion, indicating a typical liquidity event rather than a red flag for the company's fundamentals, especially given the stock's recent strong performance.
- Performance Drivers: LeMaitre Vascular reported a 16% increase in fourth-quarter sales to $64.5 million and a 47% surge in operating income to $18.8 million, driven by strong pricing and manufacturing efficiencies, highlighting its competitive edge in the global peripheral vascular market.
- Future Outlook and Risks: While the company projects approximately $280 million in full-year sales for 2026 and has raised its dividend by 25% alongside a $100 million buyback program, potential valuation creep remains a concern if growth slows, despite a strong operational outlook.
See More
LeMaitre Vascular to Participate in Five Investor Conferences
- Investor Conference Schedule: LeMaitre Vascular will participate in five investor conferences in March 2026, including the Leerink Partners Global Healthcare Conference on March 10, where management will present at 1:00 PM EDT to enhance the company's visibility among investors.
- Detailed Agenda: Following that, management will present at the Citizens Life Sciences Conference on March 11 at 1:40 PM, and will be available for one-on-one meetings at the Barclays Annual Global Healthcare Conference on March 12, further strengthening investor engagement.
- Virtual Forum Participation: At the KeyBanc Capital Markets Healthcare Forum on March 17, management will present virtually at 3:45 PM, showcasing the company's innovations and market potential in treating peripheral vascular disease.
- ROTH Conference Involvement: LeMaitre will also be available for one-on-one meetings and may participate in a presentation or fireside chat at the 38th Annual ROTH Conference from March 22-24, further expanding communication channels with investors.
See More
LeMaitre Vascular (LMAT.US) Officer Plans to Sell $10.35 Million in Common Stock via Form 144
- Stock Sale Announcement: Officer LeMaitre George intends to sell 100,000 shares of its common stock on February 26.
- Market Value: The total market value of the shares being sold is approximately $10.35 million.
See More
